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Abstract: Since the largest 2014–2016 Ebola virus disease outbreak in West Africa, understanding of 
Ebola virus infection has improved, notably the involvement of innate immune mediators. Amongst 
them, collectins are important players in the antiviral innate immune defense. A screening of Ebola 
glycoprotein (GP)-collectins interactions revealed the specific interaction of human surfactant 
protein D (hSP-D), a lectin expressed in lung and liver, two compartments where Ebola was found 
in vivo. Further analyses have demonstrated an involvement of hSP-D in the enhancement of virus 
infection in several in vitro models. Similar effects were observed for porcine SP-D (pSP-D). In 
addition, both hSP-D and pSP-D interacted with Reston virus (RESTV) GP and enhanced 
pseudoviral infection in pulmonary cells. Thus, our study reveals a novel partner of Ebola GP that 
may participate to enhance viral spread. 
Keywords: surfactant protein; SP-D; Ebola virus; Reston virus; collectin; glycoprotein; interaction; 
pig; innate immunity 
 
1. Introduction 
The Ebolavirus genus is composed of five species, Zaire ebolavirus (type virus, EBOV), Sudan 
ebolavirus (type virus, SUDV), Tai Forest ebolavirus (type virus, TAFV), Bundibugyo ebolavirus (type 
virus, BDBV), and Reston ebolavirus (type virus, RESTV). EBOV is responsible for severe, often fatal, 
hemorrhagic fever in humans and nonhuman primates (NHPs) while RESTV is nonpathogenic in 
humans, but lethal in some NHPs. The last five years have seen the emergence of Ebola outbreaks in 
unexpected or civil war locations, rendering their control extremely difficult. Since the 2014–2016 
EBOV outbreak in West Africa, our perception of the global threat posed by the Ebolavirus has 
changed [1], leading to a better understanding of how EBOV infection takes place [2]. Surprisingly, 
in numerous cases, when patients fully recovered, the virus was still present in eyes, placenta, semen, 
breast milk, and lungs, and evidence has emerged that EBOV was able to persist in immune-
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privileged sites in the body for over several months after its clearance [3–6]. Altogether these findings 
increased the concerns with regard to control and containment of possible future outbreaks, now 
including the 2018 outbreak in Congo [7,8]. Moreover, the mechanisms by which the virus causes 
disease in humans remain insufficiently understood, notably the mechanism leading to tissue 
invasion by the virus. The role of lectins has been highlighted by several authors and several members 
of this protein family have been shown to interact with the Ebola glycoprotein (GP) to modify its 
infectivity. EBOV is known to have a wide cell tropism and cell surface attachment occurs through 
GP binding to membrane co-receptors, among them lectins (dendritic cell-specific ICAM-grabbing 
non-integrin/Liver/lymph node-specific intercellular adhesion molecule-3-grabbing integrin, 
Macrophage galactose binding lectin, Liver and lymph node sinusoidal endothelial cell C-type lectin 
for DC-SIGN/L-SIGN, MGL, LSECtin, respectively) and other receptors expressed by sensitive cells 
[9–14]. Previous studies have indicated a role for endogenous circulating mannose-binding lectin 
(MBL), a member of the collectins family [15], in Ebola infection [16,17]. Depending on the serum 
conditions, MBL influences Ebola infection, resulting in an enhancement in low complement 
conditions [18]. In contrast, treatment of mice infected with EBOV using high doses of recombinant 
MBL had a protective effect [19]. Moreover, independently from the serum complement, a specific 
interaction involving ficolin-1, a member of the soluble defence collagens family, with EBOV GP 
resulted in enhancement of virus infection instead of tipping the balance towards its elimination [20]. 
In this context, we investigated the importance of pulmonary surfactant proteins A (SP-A) and 
D (SP-D), which play pivotal roles in the innate immune defense of several organs, notably lungs and 
liver, in EBOV infection. Importantly, SP-A is much more restricted to the lung while SP-D is also 
present in different mammalian mucosal tissues—including liver, spleen, kidney, lacrimal glands, 
gastrointestinal tract, and testis [21,22]—organs that are, for some of them, altered during Ebola virus 
pathology/infection [23]. 
SP-A and SP-D belong to a family of soluble humoral pattern recognition receptors known as 
the collectins. These multimeric glycoproteins play an important role in the defense against invading 
microorganisms, especially in pulmonary tissues. Direct antimicrobial neutralization (binding and 
aggregation) is often followed by a proinflammatory response to destroy the pathogen [24] and 
prevent further spread via enhanced phagocytosis of opsonized microbes via macrophages and 
neutrophils [25,26]. 
SP-D is a calcium-dependent (C-type) lectin assembled from subunits comprising a C-terminal 
globular carbohydrate recognition domain (CRD) and a triple helical collagen domain that can 
multimerize into assemblies of four trimers (dodecamers) and to a lesser extent, depending on pH 
conditions, into larger oligomers (fuzzy balls) [27]. SP-D is synthesized and constitutively secreted 
into the airspaces by two types of pulmonary epithelial cells, alveolar type II cells, and Clara cells. 
SP-D immune activity [28,29] results from its pattern recognition activity towards multiple 
carbohydrate ligands present on bacteria, fungi, or viruses [30–34]. Differences in the glycan binding 
specificities of SP-D from different animal species have been reported. Interestingly, specific 
structural features of the CRD of pSP-D, including a unique sugar binding site and an N-linked 
oligosaccharide, have been shown to contribute to its distinct activity against influenza A virus (IAV) 
[35,36]. 
Many surface viral glycoproteins have been shown to interact with SP-D, notably G and F from 
respiratory syncytial virus (RSV), HA from IAV, gp120 from HIV, and A27 from vaccinia virus 
(VACV). In several cases a protective role of SP-D against various viral pathogens has been 
demonstrated, as for IAV, RSV, and VACV [34,37–44]. At present, there is no evidence for the 
involvement of those collectins in the innate host defense against EBOV. 
The present work characterizes the interplay between EBOV and surfactant defense collectins, 
more particularly human and porcine SP-D. 
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2. Materials and Methods 
2.1. Cells 
Both Vero E6 cells (Clone E6 of African green monkey kidney cells, ATCC CRL-1586) and human 
embryonic kidney (HEK) 293T cells (ATCC CRL-1573) were grown in Dulbecco's modified Eagle 
medium (DMEM) containing 0.11 g/L pyruvate and 4.5 g/L glucose (Gibco). A549 cells (human lung 
carcinoma cell line, ATCC CCL-185) were grown in F12K medium (Gibco). For the cell culture, media 
were supplemented with 10% heat-inactivated (56°C, 30 min) fetal calf serum (FCS) (Gibco) and 1% 
antibiotics (100 U/mL of penicillin and 100 µg/mL of streptomycin, Gibco). Cells were cultured at 37 
°C in a 5% CO2 atmosphere. 
2.2. Viruses 
2.2.1. Replicative Viruses 
The recombinant vesicular stomatitis virus (VSV) expressing the glycoprotein of EBOV 
(Mayinga strain) (rVSV-GP) was generated via reverse genetics using a clone of the VSV Indiana 
serotype containing the GP EBOV open reading frames that were cloned instead of VSV G [45]. rVSV-
GP and wild-type EBOV (Mayinga) viruses were produced in Vero E6 cells in DMEM containing 3% 
FCS. rVSV-GP was propagated under BSL2 conditions and quantified using plaque forming units 
(PFU). Experiments using Ebola virus were performed in the BSL4 INSERM laboratory Jean Merieux 
(Lyon, France). EBOV was quantified via plaque assay and revealed using immunohistochemistry 
(IHC). The day before experimental infection, cells were seeded in multi-wells plates with DMEM 
medium supplemented with 5% FCS. Before virus infection, cells were rinsed with glucose-free 
DMEM (Gibco), supplemented with 1% antibiotics. Infection was performed in glucose-free DMEM, 
in the absence of FCS. For purified EBOV production (Mayinga-EBOV expressing the green 
fluorescent protein, GFP) [46,47], Vero E6 cells were progressively adapted to grow in a serum-free 
medium (VPSFM, Life Technologies, Carlsbad, CA, USA) during five passages. EBOV-GFP virus was 
inoculated at a MOI (multiplicity of infection) of 0.05 and the supernatant was harvested five days 
post-infection. The supernatant was clarified from cell debris by low speed centrifugation (1500× g, 
10 min) and then loaded over a 20% sucrose cushion in 10 mM Tris; 150 mM NaCl, 1 mM EDTA, and 
pH 7.4. Virions were pelleted using ultracentrifugation for 2 h at 134,600× g in a SW32 rotor (Beckman 
Coulter, Fullerton, CA, USA) and the pellet was suspended in 3 mL of phosphate-buffered saline 
(PBS) containing calcium and magnesium. 
2.2.2. Non-Replicative Virus 
Recombinant non-replicative vesicular stomatitis virus (VSV) particles expressing the red 
fluorescent protein (rVSV-RFP) were pseudotyped with RESTV GP (rVSV-RFP-GP-R) as described 
previously [48]. 
2.3. Reagents 
Hemagglutinin (HA) peptide, anti-HA agarose, and rabbit HA epitope tag antibody were 
purchased from Pierce, Waltham, Massachusetts, USA. Peroxidase-conjugated goat anti-rabbit and 
anti-mouse IgG antibodies were purchased from Jackson ImmunoResearch, Cambridge, UK. Both 
mouse monoclonal anti-nucleoprotein (NP) (clone ZDD4) and anti-VP40 (clone 9B2-F2) were 
produced in-house and diluted at 1:500 and 1:100, respectively. Low viscosity 
carboxymethylcellulose, mannan, and fatty acid-free bovine serum albumin (BSA) were purchased 
from Sigma Aldrich, St Louis, MO, USA. True Blue peroxidase substrate was purchased from 
Seracare KPL (Milford, MA, USA). Protein low binding (LoBind) 1.5 mL tubes were purchased from 
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Eppendorf France SAS (Montesson, France) and 1 M N-2-Hydroxyethylpiperazine-N-2-Ethane 
Sulfonic Acid (HEPES) solution was from Invitrogen (Carlsbad, CA, USA). 
2.4. Recombinant Proteins 
Recombinant MBL, produced and purified as described previously [49] was kindly provided by 
NatImmune (Copenhagen, Denmark). Recombinant human SP-D dodecamers were expressed in 
CHO-K1 cells and purified as previously described [55]. Recombinant trimeric neck + carbohydrate 
recognition domain fusion proteins (NCRDs) from human (hNCRD and the E321K mutant 
(mutNCRD)) and rat (rNCRD) species were expressed in bacteria and purified as previously 
described [50,51]. Recombinant full-length porcine SP-D (pSP-D) was produced in HEK293 cells and 
purified as described previously [52]. All preparations used for these studies had low endotoxin 
levels (ranging between 0.27–45.2 ng). AP-SP-A was a kind gift from Dr J.R. Wright (Duke University, 
Durham, North Carolina, USA). Recombinant human SP-A (rSP-A) was kindly provided by Dr F. 
McCormack (University of Cincinnati, Cincinnati, Ohio, USA). The molecular size of proteins was 
estimated as followed: 516 and 600 kDa for hSP-D and pSP-D (composed of twelve identical 
polypeptides of 43 and 50 kDa, respectively), 72 kDa for both hNCRD and mutNCRD (composed of 
three identical CRD domains of 24 kDa). Recombinant human ficolin-1 was expressed in S2 insect 
cells and purified as described previously [53]. Recombinant human ficolin-2 and ficolin-3 were 
produced in Chinese hamster ovary cells and purified by affinity chromatography on N-acetyl 
cysteine–Sepharose for ficolin-2 [54] and on acetylated BSA-Sepharose for ficolin-3 [55]. 
The recombinant GP of EBOV (Mayinga strain) was expressed in 293T cells from pDISPLAY-
HA-GP plasmid kindly provided by Pr. E. Ollmann Saphire (Scripps Institute, La Jolla, LA, USA) and 
purified as described previously [56,57]. Two kinds of trimeric recombinant GPs were used: the 
transmembrane (TM) domain-deleted protein (residues 33-632; GPΔTM) and the mucin and TM 
domains-deleted protein (GPΔTM sequence with deletion of residues 312–463, GPΔmucΔTM). The 
molecular size of soluble monomers was estimated from sodium dodecyl sulfate polyacrylamide gel 
electrophoresis SDS-PAGE analysis to 150 kDa for GPΔTM [57] and 50 kDa for GPΔmucΔTM [58]. 
His-tagged recombinant EBOV and RESTV GPs devoid of TM domain and produced in Sf9 insect 
cells (baculovirus expression system) were purchased from IBT Bioservices, Rockville, Maryland, 
USA (Z-GPΔTM-b and R-GPΔTM-b). The trimeric nature of the GP recombinant protein was assessed 
using native PAGE analysis. 
2.5. Interaction of SP-D with GP via an Overlay Assay 
One hundred microliters of purified protein solutions (1 µg/spot) were dotted onto HybondC-
extra nitrocellulose membranes (GE Healthcare Lifescience, Pittsburgh, PA, USA). Membranes were 
blocked for 1 h at room temperature (RT) in Tris-buffered saline containing 0.05% Tween 20, 10 mM 
CaCl2, and 5% skim milk. The membranes were then incubated overnight at RT in the same buffer 
containing 2 µg/mL of purified GPΔTM, washed three times for 20 min, and incubated for 1 h at RT 
with rabbit anti-HA antibody (1/200). After three 20-min washes, the membranes were incubated for 
1 h with anti-rabbit horseradish peroxidase conjugate (1/10,000). After three 20-min washes, 
interaction was detected using a chemiluminescence measurement. 
2.6. Surface Plasmon Resonance Analyses with Immobilized GP Proteins and Data Evaluation 
Surface plasmon resonance (SPR) analyses were performed on a BIAcore 3000 instrument (GE 
Healthcare, Pittsburgh, PA, USA) at 25 °C. GP proteins and fatty acid-free BSA were diluted to 10 
µg/mL in 10 mM sodium acetate, and pH 4.0, and covalently immobilized on CM5 sensor chips in 10 
mM HEPES, 150 mM NaCl, 3 mM EDTA, and pH 7.4 containing 0.005% surfactant P20 using amine 
coupling chemistry, according to the manufacturer’s instructions (GE Healthcare). Binding was 
measured at a flow rate of 20 µL/min in 50 mM triethanolamine-HCl, 145 mM NaCl, and pH 7.4, or 
in 10 mM HEPES, 150 mM NaCl, and pH 7.4, containing 0.005% surfactant P20 and 5 mM CaCl2. 
Forty microliters of each soluble analyte at the desired concentrations were injected over the 
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immobilized ligands, and the surfaces were regenerated using 10 µL injections of the running buffer 
containing 10 mM EDTA and, if needed, 1 M NaCl and 10 mM EDTA. A control flow cell submitted 
to all coupling steps without immobilized protein or with immobilized fatty acid-free BSA was used 
as a reference, and the specific binding signal was obtained through subtracting the background 
signal over the reference surface. 
Kinetic data were analyzed via global fitting to a 1:1 Langmuir binding model of both the 
association and dissociation phases for at least four SP-D concentrations simultaneously, using the 
BIAevaluation software (version 3.2, GE Healthcare). Buffer blanks were subtracted from the datasets 
used for kinetic analysis (double referencing). The apparent equilibrium dissociation constants (KDs) 
were calculated from the ratio of the dissociation constant (kd) and association rate constant (ka) (kd/ka). 
The values provided were the means ± standard deviations (SDs) from two independent experiments. 
Although the interaction of oligomeric SP-D with the trimeric GPTM was inherently more complex 
than a simple 1:1 binding model, this model was used for data fitting for comparison purposes and 
yielded satisfactory chi-square values (<2.5). 
2.7. Virus Infection Assay in the Presence of Collectins 
2.7.1. Vero E6 Experiments 
Vero E6 cells were seeded to obtain confluent plates after 24 h of culture in 24-well Multi-Well 
plates (MW). Replicative viruses (wtVSV, rVSV-GP, and EBOV), and non-replicative GP-
pseudotyped particles (rVSV-RFP-GP-R) were incubated with 10 µg/mL of defense collagens (MBL, 
AP-SP-A, hSP-D, and pSP-D) for 1 h at 37 °C in 10 mM HEPES and 5 mM CaCl2 buffer in LoBind 1.5 
mL tubes. During this time, cells were rinsed with fresh glucose-free DMEM containing 1% 
antibiotics. Then, virus-protein mixtures were incubated with cell monolayers at 37 °C in a 5% CO2 
atmosphere during one hour at the following multiplicity of infection (MOI): 5 × 10-4 for wtVSV-GP, 
1 x 10-4 for rVSV-GP, 2 × 10−4 for wt-EBOV, 2 × 10-5 for purified EBOV-serum free, and 1 for rVSV-RFP-
GP-R in 24-well culture plates. For replicative viruses, a low MOI was selected to get a PFU number 
without loss of resolution after the infection enhancement. Cells were rinsed with glucose-free 
DMEM and covered with 1.5 mL fresh medium (1:1 carboxymethylcellulose (CMC); DMEM 5% FCS), 
then cultured for an additional 48 h period and 6 days for VSV and EBOV, respectively. For VSV 
infection, cells were fixed by adding 0.75 mL of fixing and staining solution (0.2% crystal violet, 4.5% 
formaldehyde, and 7.5% ethanol in PBS) per well for 2 h. Wells were rinsed twice with water and 
PFUs were counted. For EBOV infection, the CMC-DMEM mix was removed; cells were fixed by 
adding a 4% formaldehyde-PBS solution for 10 min and permeabilized by 0.5% Triton X-100 in PBS 
for 4 min. Then, immunohistochemistry was performed with an anti-nucleoprotein (NP) antibody 
(1/500) followed by peroxidase-conjugated goat anti-mouse antibody (1/1000). Plaques were 
visualized by adding 250 µL of True Blue substrate. For the rVSV-RFP-GP-R recombinant virus 
expressing a reporter gene, cells were covered with fresh medium and cultured for an additional 8-h 
period and flow cytometry analysis was performed on a Macsquantify VYB flow cytometer (Miltenyi 
Biotech, Bergisch Gladbach, Germany) as described previously [20]. For each condition, 20,000 events 
were analyzed, and experiments were performed three times. 
2.7.2. A549 Experiments 
Similarly, A549 cells were seeded to obtain confluent plates after 24 h of culture in 24-well MW 
plates. Non-replicative GP-pseudotyped particles rVSV-RFP-GP-R were incubated with collectins. 
Then, virus-protein mixes were incubated with cell monolayer at 37 °C in 5% CO2 atmosphere during 
one hour at MOI 1. Cells were analyzed 8 hours post infection on a Macsquantify VYB flow cytometer 
(Miltenyi Biotech, Bergisch Gladbach, Germany). For each condition, 20,000 events were analyzed, 
and experiments were performed two times. 
2.9. Statistical Analyses 
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For in vitro studies, the two-tailed unpaired Student’s t-test was performed. Values of p < 0.05 
were considered significant. 
3. Results 
3.1. Identification of GP Interaction with SP-D 
The interaction of EBOV GP with human surfactant proteins was first analyzed using an overlay 
assay. Purified human alveolar proteinosis surfactant protein A (AP-SP-A), recombinant SP-A (rSP-
A), and recombinant SP-D (hSP-D) were dotted onto nitrocellulose membranes (with MBL and 
ficolin-1 as a positive control and ficolin-2 and -3 as the negative controls) and incubated with the 
soluble trimeric form of GP (GPTM). GP binding was detected using a specific anti-HA tag antibody. 
Apart from ficolin-1 and MBL, previously shown to interact with GP [20], SP-D was the only protein 
to display a robust binding signal (Figure 1A). AP-SP-A and rSP-A were devoid of GP binding 
capacity, as observed for ficolin-2 and ficolin-3 (Figure 1A and Reference [20]). 
To better characterize those interactions, SPR spectroscopy was used to investigate the 
interaction of SP proteins with GPTM. hSP-D readily bound to immobilized GP in the presence of 
calcium ions as did the positive control MBL, whereas no interaction was observed for AP-SP-A and 
rSP-A (Figure 1B), in accordance with the data obtained by the overlay assay. Binding of hSP-D to 
GP was calcium-dependent, as observed previously for MBL [20], since regeneration of the surface 
was achieved by injection of EDTA-containing solutions. 
 
Figure 1. Interaction of hSP-D with the GP of EBOV. (A) Binding detection via overlay assay. hSP-D 
was dotted onto nitrocellulose membranes and incubated with 1 µg/mL of purified HA-tagged 
GPTM. After three washes, bound GP was detected with an anti-HA tag antibody and revealed 
using enhanced chemiluminescence (ECL). GPTM (5 ng/spot) and BSA (2 µg/spot) were dotted as 
positive and negative controls, respectively. 1, hSP-D; 2, AP-SP-A; 3, rSP-A; 4, ficolin-2; 5, ficolin-1; 6, 
ficolin-3; 7, MBL; 8, BSA; 9, GPTM. (B) SPR analysis of the interaction of human collectins with 
immobilized GPTM of EBOV. Forty microliters of MBL, hSP-D, rSP-A, and AP-SP-A (2 µg/mL) were 
injected over 8000 RU of immobilized GPTM in 20 mM HEPES, 150 mM NaCl, 5 mM CaCl2, 0.005% 
surfactant P20, and pH 7.4. The specific binding signals were obtained by subtracting the background 
signals over a reference surface with 3600 RU of immobilized fatty-free BSA. The results shown are 
representative of two independent experiments. 
3.2. Characterization of SP-D Binding to GP by SPR Spectroscopy 
SPR spectroscopy was used to further characterize the interaction between hSP-D and GP. 
Increasing amounts of hSP-D were injected over the immobilized GPTM. As displayed in Figure 
2A, binding was dose-dependent and further kinetic analysis of the binding data yielded association 
and dissociation rate constants of (2.61 ± 0.92) × 106 M−1 s−1 and (3.19 ± 0.81) × 10−4 s−1, respectively, 
using a global fitting to a 1:1 Langmuir interaction model. The deduced apparent equilibrium 
dissociation constant (KD) was 0.12 ± 0.01 nM, indicative of a high affinity. 
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EBOV GP is a highly glycosylated protein and the majority of the N-glycosylation sites are 
concentrated in the glycan cap and mucin-like domain (MLD), while sialylated O-glycans are 
predominantly located in the MLD. A soluble trimeric recombinant GP, from which MLD was 
deleted (GPmucTM), was used to investigate the contribution of the MLD domain in the 
interaction with SP-D. Dose-dependent binding of hSP-D to the truncated GP was observed and 
kinetic analysis yielded ka, kd, and KD values of (3.65 ± 0.21) × 106 M−1 s−1, (1.21 ± 0.08) × 10−3 s−1, and 
0.33 ± 0.04 nM, respectively. The SP-D/GPTM complex was slightly more stable than the SP-D/ 
GPmucTM complex, as indicated by a 3–4-fold lower dissociation rate constant and the ka value 
was slightly higher in the case of GPmucTM. Despite these minor differences, these data indicate 
a high affinity binding of SP-D to both GP forms, suggesting that the mucin domain was dispensable 
for SP-D binding. 
To investigate the role of the carbohydrates in the SP-D/GP interaction, SP-D was injected over 
immobilized GP in the presence of various carbohydrate ligands. As shown in Figure 2C, SP-D 
binding was abolished in the presence of 100 µg/mL mannan, and 50% inhibition was observed in 
the presence of 5 mM mannose or 10 mM N-acetylglucosamine (GlcNAc). The isolated CRD domain 
also bound to immobilized GP, but the shape of the binding curve was different, with faster 
association and dissociation rates (Figure 2C). In addition, reduced binding was observed using the 
NCRD E321K mutant (mutNCRD) (Figure 2D), in which replacement of an acidic residue involved 
in primary calcium coordination by a lysine residue results in loss of lectin activity [59]. 
Altogether, these results indicated that the interaction of SP-D with Ebola GP was mediated via 
the calcium-dependent lectin activity of SP-D towards GP glycans, but not those located in the MLD. 
 
Figure 2. Characterization of the interaction of hSP-D with immobilized GPTM by SPR. (A,B) hSP-
D samples (40 µL) were injected at the indicated concentrations over immobilized GPTM (4,700 RU, 
panel A) or GPmucTM (2,500 RU, panel B) in 20 mM HEPES, 150 mM NaCl, 5 mM CaCl2, 0.005% 
surfactant P20, and pH 7.4 (HBSCa-P). Fits are shown as red lines and were obtained via global fitting 
of the data using a 1:1 Langmuir binding model. (C) hSP-D (3.8 nM) was injected over GPTM (8000 
RU) in HBSCa-P containing 5 mM mannose (Man), and 10 mM N-acetyl-glucosamine (GlcNAc) or 
100 µg/mL mannan. (D) hNCRD and its E321K mutant (173 nM) were injected over GPTM (8000 
RU) in HBSCa-P. (A–D) The specific binding signals shown were obtained through subtracting the 
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background signal over a reference surface with 3600 RU of immobilized fatty acid-free BSA. The 
results shown are representative of two independent experiments. 
3.3. Analysis of hSP-D and pSP-D Binding to Zaire and Reston GP Using SPR Spectroscopy 
It has been observed previously that RESTV does not cause disease in humans, whereas its 
pathogenic potential is known for monkeys and pigs; interestingly in the latter, the lung was 
identified as a critical replication site [60]. On the other hand, porcine SP-D has been shown to exhibit 
better hemagglutination activity against influenza A virus than its human counterpart, due to specific 
glycan binding features in its CRD. To investigate possible differences in the reactivity of both SP-D 
species with EBOV and RESTV, we compared the binding properties of hSP-D and pSP-D for 
recombinant GP from Zaïre and Reston Ebola viruses using SPR. Both SP-Ds bound dose-
dependently to each GP (Figure 3 A–D) and kinetic analysis of the binding curves yielded apparent 
dissociation constants (KD) in the nanomolar range (0.26–1.02 nM, see Table 1), reflective of high 
affinity. However, noticeable differences were observed in the dissociation rate constants, with values 
of 1.98 × 10−4 s−1 for hSP-D interaction with EBOV GP and of 8.28 × 10−4 s−1 for the interaction with 
RESTV GP, indicating a lower stability of the latter complexes. A similar difference was observed for 
pSP-D interaction with EBOV and REST. Conversely, the formation of the complexes with RESTV GP 
was slightly faster than that observed for EBOV GP. The affinity obtained here with recombinant 
EBOV GP expressed in insect cells and hSP-D (0.26 nM, Table 1) was in the same range as that 
obtained using the GP expressed in mammalian cells (0.33 nM) (Figure 2A). However, the ka value 
was higher for mammalian GP ((3.65 ± 0.21) × 106 M−1 s−1), which might have resulted from the 
difference in the glycosylation patterns between the recombinant GPs. 
Importantly, these in vitro interaction data did not provide evidence for a difference in the 
binding properties of porcine SP-D for RESTV compared to human SP-D. 
 
Figure 3. SPR analyses of the interaction of human and porcine SP-D with immobilized baculovirus-
expressed GPTM from Zaïre (ZGPTM-b) and Reston (RGPTM-b) ebolaviruses. (A,B) Forty 
microliters of hSP-D and pSP-D were injected at the indicated concentrations over immobilized 
ZGPTM-b (4800 RU) in 50 mM triethanolamine-HCl, 145 mM NaCl, 2 mM CaCl2, 0.005% surfactant 
P20, and pH 7.4. (C,D) hSP-D and pSP-D were injected over immobilized RGPTM-b (2,700 RU) in 
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the same buffer. (A–D) Fits shown as red lines were obtained by global fitting of the data using a 1:1 
Langmuir binding model. The specific binding signals were obtained by subtracting the background 
signal over a reference surface obtained through performing the immobilization step without added 
protein. Each kinetic analysis shown is representative of two independent experiments performed on 
separate sensor chips. 
Table 1. Kinetic and dissociation constants for the binding of human and porcine SP-D to immobilized 
GP from Zaïre and Reston Ebola viruses. 
Immobilized Ligand Soluble Analyte ka (M−1 s−1) kd (s−1) KD (M) 
ZGPTM-his human SP-D (7.49 ± 1.10) × 105 (1.98 ± 0.52) × 10-4 (2.62 ± 0.30) × 10−10 
ZGPTM-his porcine SP-D (5.35 ± 0.42) × 105 (2.28 ± 0.50) × 10-4 (4.33 ± 1.27) × 10−10 
RGPTM-his human SP-D (9.94 ± 0.37) × 105 (8.28 ± 0.23) × 10-4 (8.35 ± 0.52) × 10−10 
RGPTM-his porcine SP-D (1.29 ± 0.13) × 106 (1.31 ± 0.20) × 10-3 (1.02 ± 0.08) × 10−9 
Values are expressed as mean ± standard error of the data obtained in two separate experiments on 
different sensor chips. 
3.4. Both hSP-D and pSP-D Enhance Replicative VSV-GP and EBOV Infection 
The role of the SP-Ds interaction in virus infection was determined using a plaque assay in Vero 
E6 cells. Initial experiments were performed using a recombinant vesicular stomatitis virus 
expressing the EBOV GP spike glycoprotein (rVSV-GP) to assay the impact of the collectins on 
infection. rVSV-GP was preincubated with AP-SP-A, hSP-D, or MBL. Preincubation of the virus with 
hSP-D resulted in an increase of the virus infection compared to non-preincubated virus (p = 0.0014, 
two-tailed unpaired Student’s t-test), while no effect was observed with AP-SP-A (p > 0.05, two-tailed 
unpaired Student’s t-test) (Figure 4A). MBL was used as a positive control of GP interaction (p = 
0.0063, two-tailed unpaired Student’s t-test) as described in References [17,20]. hSP-D, preincubated 
with increasing concentrations (5, 10, and 20 µg/mL), induced a statistically significant dose–response 
enhancement of rVSV-GP infection compared to the non-preincubated virus (p = 0.040, p < 0.007 and 
p < 0.0001, respectively) (Figure 4B). pSP-D was assayed in a similar manner, which resulted in an 
increase of virus infection, as observed for hSP-D (p < 0.0001 and p < 0.0001, respectively, two-tailed 
unpaired Student’s t-test) (Figure 4C). In order to clearly differentiate plaques, a low MOI was used 
for replicative VSV-GP in these assays, which accounts for a certain variability in the pfu number/well 
obtained for the basal infection level (in the absence of added collectins). 
To confirm this observation, we next investigated whether SP-D mediated enhancement in a real 
EBOV infection model similarly as observed for rVSV-GP. Incubation of wt-EBOV with increasing 
concentrations of hSP-D (2.5, 5, and 10 µg/mL) resulted in an increase of virus infection compared 
with the non-preincubated virus (p = 0.0002, p = 0.0002, and p < 0.0001, respectively, two-tailed 
unpaired Student’s t-test), while no effect was observed with AP-SP-A (p > 0.05, two-tailed unpaired 
Student’s t-test) (Figure 4D). The role of the multimeric nature of SP-D was assayed using a hNCRD 
construct lacking the multimerization domain. As displayed in Figure 4D, hNCRD lacked the 
enhancement activity, indicating a critical role of the oligomeric form of SP-D. As the presence of the 
soluble form of the GP, as well as the presence of serum lectins, may interfere with the collectin 
binding to GP, the assay was also performed using purified EBOV produced in a serum-free 
condition. In the same way, preincubation of purified-EBOV with increasing concentrations of AP-
SP-A, hSP-D, and pSP-D (1, 5, and 10 µg/mL) resulted in an increase of virus infection for both hSP-
D and pSP-D, while no enhancement was obtained for AP-SP-A when compared with the non-
preincubated virus (p < 0.0001, p < 0.003, and p > 0.05, respectively, two-tailed unpaired Student’s t-
test) (Figure 4E). 
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Figure 4. Enhancement of replicative-GP virus infection. wtVSV-G, rVSV-GP, and EBOV were 
preincubated with collectins for 1 h at 37 °C before the infection of Vero E6 cells for 1 h at 37 °C at a 
MOI of 5 × 10-4, 1 × 10-4, and 2 x 105 in 24-well culture plates, respectively. Cells were infected with 
rVSV-GP preincubated with (A) AP-SP-A, hSP-D, and MBL (10 µg/mL), (B) increasing concentrations 
of hSP-D (5, 10, and 20 µg/mL), or (C) pSP-D (10 µg/mL). (A, B, and C) At 2 days post-infection, rVSV-
GP replication was measured through determination of the PFU number. (D) Cells were infected with 
wt-EBOV preincubated with increasing concentrations of hSP-D (2.5, 5, and 10 µg/mL), hNCRD 
(100µg/mL and 300µg/mL), and AP-SP-A (10 µg/mL). (E) Cells were infected with purified-EBOV 
preincubated with increasing concentrations of AP-SP-A, hSP-D, and pSP-D (1, 5, and 10 µg/mL). 
EBOV replication was measured at 6 days post-infection using an IHC assay. The results for the 
preincubated groups were compared to those for the nonpreincubated groups. *, a statistically 
difference (p < 0.05, two-tailed unpaired Student’s t-test). The results shown are representative of two 
independent experiments. 
3.5. SP-D-Mediated RESTV Infection Enhancement in Pulmonary Cells 
Since the routes of infection and the replication site may differ between RESTV and EBOV, we 
investigated the effect of SP-D on RESTV infection using non-replicative rVSV-RFP-GP expressing 
the RESTV GP at the surface of the viral particle (GP-R) (Figure 5A). 
When SP-Ds were preincubated with rVSV-RFP-GP-R pseudoparticles, only hSP-D enhanced 
the GP-R pseudotyped particles’ infection in VeroE6 (p = 0.0052, two-tailed unpaired Student’s t-test) 
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(Figure 5A) when compared with the non-preincubated particles. Interestingly, pSP-D had no effect 
with GP-R particles in such a model (p > 0.05, two-tailed unpaired Student’s t-test). 
As SP-D is typically synthesized and secreted using pulmonary epithelial cells, we further 
investigated the capacity of SP-D to enhance pseudovirus infection in a lung epithelium model using 
the A549 human lung adenocarcinoma cells (Figure 5B). SP-Ds were preincubated with rVSV-RFP-
GP-R pseudoparticles, and the percentage of RFP positive cells was analyzed. The capacity of hSP-D 
to enhance rVSV-RFP-GP-R particles expression was confirmed in this model (p = 0.0005, two-tailed 
unpaired Student’s t-test). Interestingly, in this pulmonary model cell, and contrary to VeroE6 cells, 
pSP-D increased the rVSV-RFP-GP-R particles’ expression (p = 0.0002, two-tailed unpaired Student’s 
t-test) compared with the non-preincubated particles. Although similar amounts of viral particles 
were used to infect VeroE6 and A549 cells, the latter were clearly less infectable than Vero cells, as 
reflected by a lower percentage of infected cells in the absence of added collectins. 
 
Figure 5. Transduction of non-replicative GP-R pseudoparticles in presence of hSP-D and pSP-D. 
rVSV-RFP-GP-R pseudoparticles were preincubated with hSP-D and pSP-D (10µg/mL) for 1 h at 37 
°C before incubation with Vero E6 cells (A) or A549 cells (B) for 1 h at 37 °C. RFP level expression was 
analyzed using flow cytometry. The results for the preincubated groups were compared to those of 
non-preincubated groups. *, a statistically difference (p < 0.05, two-tailed unaired Student’s t-test). The 
results shown are the mean of three (Vero E6 cells) and two (A549 cells) independent experiments. 
4. Discussion 
The innate immune system plays a critical role in response to viral pathogens and innate 
immune recognition proteins such as soluble defense collagens, including SP-A and SP-D, are 
important players in anti-viral defense. Inhibition of IAV using SP-D was the best characterized, but 
other viruses, such as RSV and VACV, were also reported to be inhibited by SP-D [34,39]. A common 
inhibition mechanism involves the calcium-dependent interaction of SP-D's CRD domain with sugars 
localized on the virus spike glycoprotein leading to neutralization of viral infection. However, in rare 
cases, SP-D was described to facilitate infection, as illustrated for Aspergillus fumigatus [61] and 
Pneumocystis pneumonia [62]. In this context, our study shows for the first time that SP-D interaction 
with a viral glycoprotein can enhance virus infection in mammalian cells. 
The interaction between purified EBOV and Reston GP and hSP-D and pSP-D was characterized 
using SPR analyses. Both hSP-D and pSP-D bound to GP with a high affinity and the interaction 
involved calcium-dependent binding of the lectin CRD domain to GP glycans. Additionally, the 
shape of hNCRD-GP SPR binding curve which displays faster association and dissociation rates 
stresses the importance of the avidity provided by the multimerization of the full-length protein. This 
avidity seems crucial for infection enhancement as hNCRD, while being able to interact with GP, did 
not induce infection enhancement. Importantly, we showed that SP-D also interacted with GP 
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exposed at the surface of VSV particles or genuine EBOV, resulting in enhanced infection of Vero 
cells. While MBL was the first soluble lectin described to bind EBOV GP and to enhance Ebola virus 
infection in low complement conditions [18], we have recently shown that a second lectin-like 
protein, ficolin-1, also contributes to the enhancement of EBOV infection, independent of the serum 
complement level [20]. Ficolin-1 interaction with EBOV-GP was mediated via the fibrinogen-like 
recognition domain of ficolin-1 and the mucin-like domain of GP through its sialylated moieties 
residues. In contrast, the interaction of SP-D described in this study was maintained in the absence 
of the GP mucin domain, as observed previously for MBL [16,18,20]. Interestingly, purified SP-A did 
not interact with EBOV GP and logically displayed no ability to modulate EBOV infection. The 
difference between SP-A and SP-D might arise from: i) the different oligomeric organization of SP-A 
(hexameric, bouquet-like structure) and SP-D (dodecameric, cross-shaped structure), which can 
result in variations of spatial organization of their trimeric CRDs, influencing the binding for 
carbohydrate ligand patterns present on EBOV GP; and ii) their differences in sugar binding 
specificity. The latter hypothesis seems more plausible since MBL, which has an oligomeric 
organization close to that of SP-A, did interact with EBOV-GP. 
Membrane anchored C-type lectins are involved in EBOV infection. Cell surface attachment of 
EBOV occurs notably through GP binding to membrane lectins (DC-SIGN/L-SIGN, MGL, LSECtin 
and Myeloid LSECtin) [9–12,14], an interaction that promotes virus entry in various cell types. In this 
study, SP-D was identified as a new soluble lectin involved in EBOV host cell infection. This result 
suggests that SP-D likely acts as a multivalent bridging molecule to facilitate attachment of SP-D-
bound virus to host cell co-receptors, in accordance with the lack of viral infection enhancement 
observed when wt-EBOV was preincubated with hNCRD. Candidate collectin receptors on epithelial 
cells that may interact with the collagen-like regions of SP-D include the calreticulin/CD91 complex 
[63], the integrin 22 [64], and possibly a yet unidentified SP receptor described by Jakel et al. [65]. 
In addition to facilitating the attachment of the virus particles to host cells, the interaction of virus-
bound SP-D to the collagen receptors may have consequences on the modulation of the inflammatory 
response [66]. 
Interestingly, hSP-D is also secreted in other parts of the human body as the liver (the major 
Ebola virus target), spleen, kidney, lacrimal glands, gastrointestinal tract, and testis [21,22]. Most of 
these sites are known for EBOV replication [23], which raises the possibility that SP-D may also 
influence infection in several tissues. Interestingly, since SP-D was identified as a new serum 
biomarker of lung infection [67] or lung injury, it may be useful to assay SP-D serum level as a 
possible indicator of EBOV pathology progression. 
RESTV is unique among ebolaviruses because it does not cause disease in humans [68] or in pig 
in absence of co-infection [60]. RESTV capacity to infect some animal species exists while the reasons 
of its non-pathogenicity in humans are not clear. A recent study showed that extended glycans on 
Reston GP are involved in reduced lectin-mediated viral infectivity of RESTV compared to EBOV 
[69]. In our study, we did not detect significant differences between hSP-D and pSP-D regarding their 
capacity to interact with EBOV GP and to enhance infection, which could explain that EBOV 
replication was observed in the lungs of infected pigs [70–72]. In line with their common capacity to 
interact with RESTV GP, both hSP-D and pSP-D were able to enhance infection of pulmonary (A549) 
cells. However, no significant enhancement of infection was observed for pSP-D in the case of non-
pulmonary (Vero E6) cells, which was unexpected, given the similar data obtained in SPR 
experiments for the interaction of pSP-D with the GP of EBOV or RESTV. This suggests that 
extrapolation of binding data obtained with purified recombinant proteins to a context of cell 
infection with viral pseudoparticles might be too simplistic. In addition, the different origin of the 
non-pulmonary and pulmonary cells used (monkey vs human) does not allow direct comparison of 
the tissue specificity of human and porcine SP-D. Whether our observations reflect differences in the 
pathogenesis of RESTV in pig remains to be investigated. Future studies should be conducted to 
increase the knowledge on tissue tropism and the involvement of soluble lectins, notably through the 
use of ex vivo culture systems of different species and more filoviruses (notably RESTV). 
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In conclusion, SP-D was identified as a new interacting partner of Ebola GP, contributing in the 
enhancement of infection instead of providing a first line of defense by inhibiting/neutralizing the 
virus. Thus ficolin-1, SP-D, and MBL may constitute a viral network of lectin partners used to subvert 
the innate immune system and promote host cells invasion. Further studies are needed to investigate 
the underlying mechanisms and the possible role of SP-D in Ebola virus in vivo pathogenesis. 
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